New insights on the antitumoral properties of prodiginines

Current Medicinal Chemistry

Volumn 17, Issue 21, 2010, Pages 2222-2231

  Perez Tomas R ^a   Vinas M ^b  

^a Cancer Cell Biology Research Group   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Cancer; Prodiginines

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BUTYL 3 CYCLO HEPTYLPROGININE; CISPLATIN; CYCLOPRODIGIOSIN; INDOL PRODIGIOSIN; MITOGEN ACTIVATED PROTEIN KINASE; N ALKYLATED PRODIGIOSIN; OBATOCLAX; PRODIGININE DERIVATIVE; PRODIGIOSIN; UNCLASSIFIED DRUG; UNDECILPRODIGIOSIN; PRODIGININE; PYRROLE DERIVATIVE;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CELL CYCLE ARREST; CLINICAL TRIAL; DNA DAMAGE; HUMAN; MANTLE CELL LYMPHOMA; SERRATIA MARCESCENS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; APOPTOSIS; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; SERRATIA; TOXICITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; DNA DAMAGE; HUMANS; NEOPLASMS; PRODIGIOSIN; PYRROLES; SERRATIA; SIGNAL TRANSDUCTION;

EID: 77955698213     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791331103     Document Type: Article

References (105)

1. Williams, R.P.; Qadri, S.M.H. The pigment of Serratia. In: The genus Serratia CRC press. Raton Fl. 1980.
2. Grimont, P.A.; Grimont, F. Biotyping of Serratia marcescens and its use in epidemiological studies.J. Clin. Microbiol., 1978, 8, 73-83.
3. Von Grevenitz, A.; Infection and colonization with Serratia. In: The genus Serratia CRC press. Boca Raton Fl. 1980.
4. Alihosseini, F.; Ju, K.S.; Lango, J.; Hammock, B.D.; Sun, G. Antibacterial colorants: characterization of prodiginines and their applications on textile materials. Biotechnol. Prog., 2008, 24,742-747.
5. Coderch, N.; Piqué, N.; Lindner, B.; Abitiu, N.; Merino, S.; Izquierdo, L.; Jimenez, N.; Tomás, J.M.; Holst, O.; Regué, M. Genetic and structural characterization of the core region of the lipopolysaccharide from Serratia marcescens N28b (serovar O4). J. Bacteriol., 2004, 186, 978-988.
6. Rubirés, X.; Saigi, F.; Piqué, N.; Climent, N.; Merino, S.: Albertí, S.; Tomás, J.M.; Regué, M. A gene (wbbL) from Serratia marcescens N28b (O4) complements the rfb-50 mutation of Escherichia coli K-12 derivatives. J. Bacteriol., 1997, 179, 7581-7586.
7. Palomar, J.; Guasch, J.F.; Regué, M.; Viñas, M. The effect of nuclease on transformation efficiency in Serratia marcescens. FEMS Microbiol. Lett., 1990, 57, 255-258.
8. Puig, M.; Fusté, M.C.; Viñas, M. Outer membrane proteins from Serratia marcescens. Can. J. Microbiol., 1993, 39, 108-111.
9. Zimmermann, W.; Rosselet, A. Antimicrob. Agents. Chemother., 1977, 12,368-372.
10. Ruiz, N.; Montero, T.; Hernandez-Borrell, J.; Viñas, M. The role of Serratia marcescens porins in antibiotic resistance. Microb. Drug Resist., 2003, 9, 257-264.
11. Ruiz N.; Merino, S.; Viñas, M.; Domènech, O.; Montero, M.T.; Hernández-Borrell, J. Preliminary studies of the 2D crystallization of Omp1 of Serratia marcescens: observation by atomic force microscopy in native membranes environment and reconstituted in proteolipid sheets. Biophys. Chem., 2004, 111, 1-7.
12. Ruiz, N.; Maier, E.; Andersen, C.; Benz, R.; Viñas, M. Molecular and functional characterisation of the Serratia marcescens outer membrane protein Omp1. Biophys. Chem., 2004, 109, 215-227.
13. Berlanga, M.; Vázquez, J.L.; Hernandez-Borrell, J.; Montero, M.T.; Viñas, M. Evidence of an efflux pump in Serratia marcescens. Microb. Drug Resist., 2000, 6, 111-117.
14. Berlanga, M.; Ruiz, N.; Hernandez-Borrell, J.; Montero, M.T.; Viñas, M. Role of the outer membrane in the accumulation of quinolones by Serratia marcescens. Can. J. Microbiol., 2000, 46, 716-722.
15. Berlanga, M.; Viñas, M. Salicylate induction of phenotypic resistance to quinolones in Serratia marcescens. J. Antimicrob. Chemother., 2000, 46, 279-282.
16. Kumar, A.; Worobec, E.A. Fluoroquinolone resistance of Serratia marcescens: involvement of a proton gradient-dependent efflux pump. J. Antimicrob. Chemother., 2002, 50, 593-596.
17. Chen, J.; Kuroda, T.; Huda, M.N.; Mizushima, T.; Tsuchiya, T. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. J. Antimicrob. Chemother., 2003, 52, 176-179.
18. Gristwood, T.; Fineran, P.C.; Everson, L.; Salmond, G.P. PigZ, a TetR/AcrR family repressor, modulates secondary metabolism via the expression of a putative four-component resistance-nodulationcell- division efflux pump, ZrpADBC, in Serratia sp. ATCC 39006. Mol. Microbiol., 2008, 69, 418-435.
19. Gargallo, D.; Lorén, J.G.; Guinea, J.; Viñas, M. Glucose-6- phosphate dehydrogenase alloenzymes and their relationship to pigmentation in Serratia marcescens. Appl. Environ. Microbiol., 1987, 53, 1983-1986.
20. Purkayastha, M.; Williams, R.P.W. Association of pigment with the cell envelope of Serratia marcescens (Chromobacterium prodigiosum). Nature, 1960, 187, 349-350.
21. Tsang, J.C.; Kallvy, D.M. Association of prodigiosin with outer cell wall components. Trans Ill. State. Acad. Sci. 1971, 64, 22-31.
22. Cruz-Camarillo, R.; Sanchez-Zuñiga, A.A.; Complex proteinprodigiosin in Serratia marcescens. Nature, 1968, 218, 567-568.
23. Viñas, M.; Loren, J.G.; Guinea, J. Particulate-bound pigmentg of Serratia marcescens. Microbios Lett., 1983, 24, 19-26.
24. Grimont, P.A.; Grimont, F. Biotyping of Serratia marcescens and its use in epidemiological studiesJ. Clin. Microbiol., 1978, 8,73-83.
25. Gerber, N.N. Prodigiosin-like pigments. CRC. Crit. Rev. Microbiol., 1975, 3, 469-485.
26. Abrahantes-Pérez, M.C.; Reyes-González, J.; Véliz-Ríos, G.; Bequet-Romero, M.; Gómez-Riera, R.; Anais-Gasmury, C.; Huerta, V.; González, L.J.; Canino, C.; Garcia, J.; Váldez, J.; Reyes, B.; Váldes, R.; Martínez, E. Cytotoxic proteins combined with prodigiosin obtained from Serratia marcescens have both broad and selective cytotoxic activity on tumor cells. J. Chemother., 2006, 18,172-181.
27. Solé, M.; Rius, N.; Lorén, J.G. Rapid extracellular acidification induced by glucose metabolism in non-proliferating cells of Serratia marcescens. Int. Microbiol., 2000, 3, 39-43.
28. Lorén, J.G.; Guinea, J. Effect of glucose concentration on the biosynthesis of prodigiosin by Serratia marcescens. Rev. Esp. Fisiol., 1978, 34, 247-252.
29. Qadri, S.M.; Williams, R.P. Induction of prodigiosin biosynthesis after shift-down in temperature of nonproliferating cells of Serratia marcescens. Appl. Microbiol., 1972, 23, 704-709.
30. Qadri, S.M.; Williams, R.P. Biosynthesis of the tripyrrole bacterial pigment, prodigiosin, by nonproliferating cells of Serratia marcescens. Tex. Rep. Biol. Med., 1972, 30, 73-85.
31. Williams, R.P.; Gott, C.L.; Qadri, S.M. Induction of pigmentation in nonproliferating cells of Serratia marcescens by addition of single amino acids. J. Bacteriol., 1971, 106, 444-448.
32. Williams, R.P.; Gott C.L.; Qadri, S.M.; Scott R.H. Influence of temperature of incubation and type of growth medium on pigmentation in Serratia marcescens. J. Bacteriol., 1971, 106, 438-443.
33. Viñas, M.; El-Ebiary, A.; Lorén, J.G.; Guinea, J. Effect of gramicidin A and valinomycin on prodigiosin production by nonproliferating Serratia marcescens J. Antibiot., 1987, 40, 113-115.
34. Lauferska, U.; Vinas, M.; Lorén, J.G.; Guinea, J. Enhancement by polymyxin B of proline-induced prodigiosin biosynthesis in nonproliferating cells of Serratia marcescens. Microbiologica, 1983, 6, 155-162.
35. Leranoz, A.M.; Fusté, M.C.; Viñas, M.; Hull, R.A.; Williams, R.P. Cloning and expression in Escherichia coli of a gene encoding proline oxidase of Serratia marcescens. Microbios., 1991, 67, 87-94.
36. Trias, J.; Viñas, M.; Guinea, J.; Lorèn, J.G. Brown pigmentation in Serratia marcescens cultures associated with tyrosine metabolism. Can. J. Microbiol., 1989, 35, 1037-1042.
37. Trias, J.; Viñas, M.; Guinea, J.; Lorèn, J.G. Induction of Yellow Pigmentation in Serratia marcescens. Appl. Environ. Microbiol., 1988, 54, 3138-3141.
38. Trias, J.; Viñas, M.; Guinea, J.; Lorèn, J.G. A method for the enrichment of auxotrophic mutants of Serratia marcescens by using azthreonam. Lett. Appl. Microbiol.,1984, 4, 81-85.
39. Trias, J.; Viñas, M.; Guinea, J.; Lorèn, J.G. Isolation from urine of two Serratia marcescens strains excreting a diffusible yellow pigment. J. Gen. Microbiol., 1987, 133, 773-777.
40. Pérez-Tomás, R.; Montaner, B.; Llagostera, E.; Soto-Cerrato, V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem. Pharmacol., 2003, 66, 1447-1452.
41. Williamson, N.; Fineran, P.; Leeper, F.; Salmond, G. The biosynthesis and regulation of bacterial prodiginines. Nature Rev. Microbiol., 2006, 4, 887-899.
42. Regourd, J.; Ali, A.; Thompson, A. Synthesis and anti-cancer activity of C-ring-functionalized prodigiosin analogues. J. Med. Chem., 2007, 50, 1528-1536.
43. Yamamoto, C.; Takemoto, H.; Kuno, K.; Yamamoto D.; Tsubura A.; Kamata K.; Hirata H.; Yamamoto A.; Kano H.; Seki T.; Inoue K. Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology., 1999, 30, 894-902.
44. Zhang, J.; Shen, Y.; Liu, J.; Wei, D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem. Pharmacol., 2005, 69, 407-414.
45. Soto-Cerrato, V.; Llagostera, E.; Montaner, B.; Scheffer, GL.; Pérez-Tomás, R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem. Pharmacol., 2004, 68, 1345-1352.
46. Llagostera, E.; Soto-Cerrato, V.; Joshi, R.; Montaner, B.; Gimenez-Bonafe, P.; Pérez-Tomás, R. High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anticancer Drugs, 2005, 16, 393-399.
47. Soto-Cerrato, V.; Viñals, F.; Lambert, J.; Kelly, J.; Pérez-Tomás, R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol. Cancer Ther., 2007, 6, 362-369.
48. Adams, J.M. Ways of dying: multiple pathways to apoptosis. Genes Dev., 2003, 17, 2481-2495.
49. Debatin, K.M.; Krammer, P.H. Death receptors in chemotherapy and cancer. Oncogene, 2004, 23, 2950-2966.
50. Igney F.; Krammer, P.; Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer, 2002, 2, 277-288.
51. Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2,647-656.
52. Schuler, M.; Green, D.R. Mechanisms of p53-dependent apoptosis. Biochem. Soc. Trans., 2001, 29, 684-688.
53. Ho, T. F.; Peng, Y.T.; Chuang, S.M.; Lin, S.CH.; Feng, B.L.; Lu, Ch.H.; Yu, W.J.; Chang, J.S.; Chang, Ch.Ch. Prodigiosin downregulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Tox. Appl. Pharmacol., 2009, 235, 253-260.
54. Nguyen, M.; Marcellus R.C.; Roulston, A.; Watson, M.; Serfass, L.; Madiraju, M.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johstone, R.W.; Beauparlant, P.; Shore, G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS, 2007, 104, 19512-19517.
55. Pérez-Galan, P.; Roué, G.; Nguyen, M.; Montserrat, E.; Shore, G.C.; Campo, E.; Colomer,D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, 22, 1722-1720.
56. Witters, L.M.; Witkoski, A.; Planas-Silva, M.D.; Berger, M.; Lipton, A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol. Reports., 2007, 17, 465-469.
57. Li J.; Viallet, J.; Haura, E.B. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatininduced apoptosis in non-small cell lung cancer cells. Cancer Chemother. Pharmacol., 2008, 61,525-534.
58. Perez-Galan, P.; Roué, G.; Campo, E.; Colomer, D. The BH3- mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.Blood., 2007, 109, 4441-4449.
59. Trudel, S.; Li, Z.H.; Rauw, J.; Tiedemann, R.E.; Wen, X.Y.; Stewart, K. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 2007, 109, 5430-5438.
60. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Harris, D.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; Andreff, M. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res., 2008, 68, 3413-3420.
61. Lagadic-Gossmann, D.; Huc, L.; Lecureur, V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ. 2004,11, 953-961.
62. Yamamoto, D.; Uemura, Y.; Tanaka, K.; Nakai K.; Yamamoto C.; Takemoto H.; Kamata K.; Hirata H.; Hioki K. Cycloprodigiosin hydrochloride, H(+)/CL(-) symporter, induces apoptosis and differentiation in HL-60 cells. Int. J. Cancer, 2000, 88, 121-128.
63. - symporters that uncouple proton translocators. J. Biol. Chem., 1998, 273, 21455-21462.
64. Nakayasu, T.; Kawauchi, K.; Hirata, H.; Shimmen, T. Demonstration of Cl- requirement for inhibition of vacuolar acidification by cycloprodigiosin in situ. Plant Cell Physiol., 2000, 41, 857-863.
65. Kataoka, T.; Muroi, M.; Ohkuma, S.; Waritani T.; Magae J.; Takatsuki A.; Kondo S., Yamasaki M.; Nagai K. Prodigiosin 25-C uncouples vacuolar type H(+)-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett., 1995, 359, 53-59.
66. Ohkuma, S.; Sato, T.; Okamoto, M.; Matsuya H.; Arai K.; Kataoka T.; Nagai K.; Wasserman H.H. Prodigiosins uncouple lysosomal vacuolar-type ATPase through promotion of H+/Cl- symport. Biochem. J. 1998, 334, 731-741.
67. Matsuya, H.; Okamoto, M.; Ochi, T., Nishikawa A., Shimizu S., Kataoka T., Nagai K., Wasserman H.H.; Ohkuma S. Reversible and potent uncoupling of hog gastric (H(+)+K(+))-ATPase by prodigiosins. Biochem. Pharmacol., 2000, 60, 1855-1863.
68. Konno, H.; Matsuya, H.; Okamoto M.; Sato T.; Tanaka Y.; Yokoyama K.; Kataoka T.; Nagai K.; Wasserman H.H.; Ohkuma S. Prodigiosins uncouple mitochondrial and bacterial F-ATPases: evidence for their H+/Cl- symport activity. J. Biochem. (Tokyo).,1998, 124, 547-556.
69. Francisco, R.; Pérez-Tomás, R.; Gimenez-Bonafe, P.; Soto-Cerrato, V.; Gimenez-Xavier, P.; Ambrosio, S. Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur. J. Pharmacol., 2007, 572,111-119.
70. Gale, P.A. Amidopyrroles: from anion receptors to membrane transport agents. Chem. Commun. (Camb)., 2005, 30, 3761-3772.
71. Gale, P.A.; Light, M.E.; McNally, B.; Navakhun, K.; Sliwinski, K.E.; Smith, B.D. Co-transport of H+/Cl- by a synthetic prodigiosin mimic. Chem. Commun. (Camb)., 2005, 30, 3773-3775.
72. Díaz, R.I.; Regourd, J.; Santacroce, P.V.; Davis, J.T.; Jakeman, D.L.; Thompson, A. Chloride anion transport and copper-mediated DNA cleavage by C-ring functionalized prodigiosenes. Chem. Commun. (Camb)., 2007, 26, 2701-2703.
73. Sessler, J.L.; Eller, L.R.; Cho, W.S.; Nicolaou S.; Aguilar A., Lee J.T.; Lynch V.M.; Magda D.J. Synthesis, anion-binding properties, and in vitro anticancer activity of prodigiosin analogues. Angew. Chem. Int. Ed. Engl., 2005, 44, 5989-5992.
74. Seganish, J.L.; Davis, J.T. Prodigiosin is a chloride carrier that can function as an anion exchanger. Chem. Commun. (Camb)., 2005, 46, 5781-5783.
75. Castillo-Avila, W.; Abal, M.; Robine, S.; Pérez-Tomás, R. Nonapoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci., 2005, 78, 121-127.
76. Babior, B. NADPH oxidase. Curr. Opin. Immunol., 2004, 16, 42-47.
77. Nakashima, T.; Iwashita, T.; Fujita, T.; Sato, E.; Niwano, Y.; Kohno, M.; Kuwahara, S.; Harada, N.; Takeshita, S.; Oda, T. A prodigiosin analogue inactivates NADPH oxidase in macrophage cells by inhibiting assembly of p47phox and Rac. J. Biochem. 2008, 143, 107-115.
78. Roos, W.P.; Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006, 12, 440-450.
79. Melvin, MS; Ferguson, DC; Lindquist, N.; Manderville, RA. DNA Binding by 4-Methoxypyrrolic Natural Products. Preference for Intercalation at AT Sites by Tambjamine E and Prodigiosin. J. Org. Chem., 1999, 64, 6861-6869.
80. Montaner, B.; Castillo-Avila, W.; Martinell, M.; Ollinger R.; Aymami J.; Giralt E.; Pérez-Tomás R. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicol. Sci., 2005, 85, 870-879.
81. Manderville, R.A. Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products. Curr. Med. Chem. Anti-Cancer Agents, 2001, 1, 195-218.
82. Melvin, M.S.; Tomlinson, J.T.; Saluta, G.R.; Kucera, G.L.; Lindquist, N. Manderville, R.A. DNA Cleavage by Copper·Prodigiosin. J. Am. Chem. Soc., 2000, 122, 6333-6334.
83. Melvin, M.S.; Wooton, K.E.; Rich, C.C.; Saluta, G.R., Kucera, G.L.; Lindquist, N.; Manderville R.A. Copper-nuclease efficiency correlates with cytotoxicity for the 4-methoxypyrrolic natural products. J. Inorg. Biochem., 2001, 87, 129-135.
84. Melvin, M.S.; Tomlinson, J.T.; Park, G.; Day C.S.; Saluta G.R.; Kucera G.L.; Manderville R.A. Influence of the a-ring on the proton affinity and anticancer properties of the prodigiosins. Chem. Res. Toxicol., 2002, 15, 734-741.
85. Melvin, M.S.; Calcutt, M.W.; Noftle, R.E.; Manderville, R.A. Influence of the a-ring on the redox and nuclease properties of the prodigiosins: importance of the bipyrrole moiety in oxidative DNA cleavage. Chem. Res. Toxicol., 2002, 15, 742-748.
86. Fürstner, A.; Grabowski, E.J. Studies on DNA cleavage by cytotoxic pyrrole alkaloids reveal the distinctly different behavior of roseophilin and prodigiosin derivatives. Chembiochem., 2001, 2, 706-709.
87. Park, G.; Tomlinson, J.T.; Melvin, M.S.; Wright, M.W.; Day, C.S., Manderville, R.A. Zinc and copper complexes of prodigiosin: implications for copper-mediated double-strand DNA cleavage. Org. Lett., 2003, 5, 113-116.
88. Baldino, C.M.; Parr, J.; Wilson, C.J.; Ng, S.C.; Yohannes, D.; Wasserman, H.H. Indoloprodigiosins from the C-10 bipyrrolic precursor: new antiproliferative prodigiosin analogs. Bioorg. Med. Chem. Lett., 2006, 16, 701-704.
89. Lawrence, M.C.; Jivan, A.; Shao, C.; Duan, L.; Goad, D.; Zaganjor, E.; Osborne J.; McGlynn, K.; Stippec, S.; Earnest, S.; Chen, W.; Cobb, M.H. The roles of MAPKs in disease. Cell Res., 2008, 18, 436-442.
90. Pandey, R.; Chander, R.; Sainis, K,B. Prodigiosins: a novel family of immunosuppressants with anti-cancer activity. Indian J. Biochem. Biophys. 2007, 44, 295-302.
91. Montaner B.; Pérez-Tomás R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol Lett., 2002, 129, 93-98.
92. Montaner-Ramoneda B.; Pérez-Tomás R. Activation of protein kinase C for protection of cells against apoptosis induced by the immunosuppressor prodigiosin. Biochem Pharmacol., 2002, 63, 463-469.
93. Soto-Cerrato, V.; Vinals, F.; Lambert, J.R.; Kelly, J.A.; Pérez-Tomás, R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol. Cancer Ther., 2007, 6, 362-369.
94. Deorukhkar A.A.; Chander R.; Pandey R., Sainis K.B. A novel Nalkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type. Cancer Chemother. Pharmacol., 2008, 61, 355-363.
95. Fürstner, A.; Reinecke, K.; Prinz, H.; Waldmann, H. The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors. Chembiochem, 2004, 5, 1575-1579.
96. Songia, S.; Mortellaro, A.; Taverna, S.; Fornasiero C.; Scheiber E.A.; Erba E.; Colotta F.; Mantovani A.; Isetta A.M.; Golay J. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclindependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J. Immunol., 1997, 158, 3987-3995.
97. Pérez-Tomás R.; Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol. Histopathol., 2003, 18, 379-385.
98. Benczik, M.; Gaffen, S.L. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol. Invest., 2004, 33, 109-142.
99. Sigal, N.H.; Dumont, F.J. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu. Rev. Immunol., 1992, 10, 519-560.
100. Mortellaro, A.; Songia, S.; Gnocchi, P.; Ferrari, M.; Fornasiero, C.; D'Alessio, R.; Isetta, A.; Colotta, F.; Golay, J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation. J. Immunol., 1999, 162, 7102-7109.
101. Han, S.B.; Park, S.H.; Jeon, Y.J.; Kim, Y.K.; Kim, H.M.; Yang, K.H. Prodigiosin blocks T cell activation by inhibiting interleukin-2Ralpha expression and delays progression of autoimmune diabetes and collagen-induced arthritis. J. Pharmacol. Exp. Ther. 2001, 299, 415-425.
102. Adcock, I.M. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi. Arch. Chest Dis. 1997, 52, 178-186.
103. Brasier, A.R. The NF-B regulatory network. Cardiovasc. Toxicol. 2006, 6, 111-130.
104. Kamata, K, Okamoto, S, Oka, S, Kamata, H, Yagisawa, H, and Hirata, H. Cycloprodigiosin hydrocloride suppresses tumor necrosis factor (TNF) alpha-induced transcriptional activation by NFkappaB. FEBS Lett., 2001,507, 74-80.
105. Stepkowski, S.M.; Erwin-Cohen, R.A.; Behbod, F.; Wang, M.E.; Qu, X.; Tejpal, N.; Nagy, Z.S.; Kahan, B.D.; Kirken, R.A. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood, 2002, 99, 680-689.